Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Nanoxel and Herzuma as First-line Chemotherapy in Patients With Metastatic Salivary Duct Carcinoma : Open Label Single Arm Multicenter Phase II Study

NCT03614364 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03614364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03614364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Nanoxel and Herzuma as First-line Chemotherapy in Patients With Metastatic Salivary Duct Carcinoma : Open Label Single Arm Multicenter Phase II Study
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
September 20, 2018
Completion date
August 31, 2023
Enrollment
41 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

salivary duct carcinoma